Literature DB >> 30467186

γδ T cells for immunotherapy.

Meixiao Long1.   

Abstract

Mesh:

Substances:

Year:  2018        PMID: 30467186      PMCID: PMC6251004          DOI: 10.1182/blood-2018-10-876078

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  10 in total

1.  Ibrutinib treatment improves T cell number and function in CLL patients.

Authors:  Meixiao Long; Kyle Beckwith; Priscilla Do; Bethany L Mundy; Amber Gordon; Amy M Lehman; Kami J Maddocks; Carolyn Cheney; Jeffrey A Jones; Joseph M Flynn; Leslie A Andritsos; Farrukh Awan; Joseph A Fraietta; Carl H June; Marcela V Maus; Jennifer A Woyach; Michael A Caligiuri; Amy J Johnson; Natarajan Muthusamy; John C Byrd
Journal:  J Clin Invest       Date:  2017-07-17       Impact factor: 14.808

Review 2.  Tumor-induced host immunosuppression: special focus on CLL.

Authors:  Christine E Cutucache
Journal:  Int Immunopharmacol       Date:  2013-06-07       Impact factor: 4.932

Review 3.  Perturbation of the normal immune system in patients with CLL.

Authors:  Francesco Forconi; Paul Moss
Journal:  Blood       Date:  2015-06-17       Impact factor: 22.113

4.  Improving CLL Vγ9Vδ2-T-cell fitness for cellular therapy by ex vivo activation and ibrutinib.

Authors:  Iris de Weerdt; Tom Hofland; Roeland Lameris; Sanne Endstra; Aldo Jongejan; Perry D Moerland; Renee C G de Bruin; Ester B M Remmerswaal; Ineke J M Ten Berge; Nora Liu; Mario van der Stelt; Laura M Faber; Mark-David Levin; Eric Eldering; Sanne H Tonino; Tanja D de Gruijl; Hans J van der Vliet; Arnon P Kater
Journal:  Blood       Date:  2018-09-13       Impact factor: 22.113

5.  Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL.

Authors:  Wei Ding; Betsy R LaPlant; Timothy G Call; Sameer A Parikh; Jose F Leis; Rong He; Tait D Shanafelt; Sutapa Sinha; Jennifer Le-Rademacher; Andrew L Feldman; Thomas M Habermann; Thomas E Witzig; Gregory A Wiseman; Yi Lin; Erik Asmus; Grzegorz S Nowakowski; Michael J Conte; Deborah A Bowen; Casey N Aitken; Daniel L Van Dyke; Patricia T Greipp; Xin Liu; Xiaosheng Wu; Henan Zhang; Charla R Secreto; Shulan Tian; Esteban Braggio; Linda E Wellik; Ivana Micallef; David S Viswanatha; Huihuang Yan; Asher A Chanan-Khan; Neil E Kay; Haidong Dong; Stephen M Ansell
Journal:  Blood       Date:  2017-04-19       Impact factor: 22.113

6.  Exhausting T cells in CLL.

Authors:  Thorsten Zenz
Journal:  Blood       Date:  2013-02-28       Impact factor: 22.113

7.  Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes.

Authors:  Jason A Dubovsky; Kyle A Beckwith; Gayathri Natarajan; Jennifer A Woyach; Samantha Jaglowski; Yiming Zhong; Joshua D Hessler; Ta-Ming Liu; Betty Y Chang; Karilyn M Larkin; Matthew R Stefanovski; Danielle L Chappell; Frank W Frissora; Lisa L Smith; Kelly A Smucker; Joseph M Flynn; Jeffrey A Jones; Leslie A Andritsos; Kami Maddocks; Amy M Lehman; Richard Furman; Jeff Sharman; Anjali Mishra; Michael A Caligiuri; Abhay R Satoskar; Joseph J Buggy; Natarajan Muthusamy; Amy J Johnson; John C Byrd
Journal:  Blood       Date:  2013-07-25       Impact factor: 22.113

Review 8.  Ibrutinib: a first in class covalent inhibitor of Bruton's tyrosine kinase.

Authors:  Matthew S Davids; Jennifer R Brown
Journal:  Future Oncol       Date:  2014-05       Impact factor: 3.404

Review 9.  T-cell receptor-engineered T cells for cancer treatment: current status and future directions.

Authors:  Yu Ping; Chaojun Liu; Yi Zhang
Journal:  Protein Cell       Date:  2017-01-20       Impact factor: 14.870

Review 10.  Molecular Determinants of Target Cell Recognition by Human γδ T Cells.

Authors:  André E Simões; Biagio Di Lorenzo; Bruno Silva-Santos
Journal:  Front Immunol       Date:  2018-04-27       Impact factor: 7.561

  10 in total
  1 in total

Review 1.  Effects of ibrutinib on T-cell immunity in patients with chronic lymphocytic leukemia.

Authors:  Yanyan Liu; Yongping Song; Qingsong Yin
Journal:  Front Immunol       Date:  2022-08-19       Impact factor: 8.786

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.